Legal Information
Luminex is a registered trademark of Luminex Corp
MILLIPLEX is a registered trademark of Merck KGaA, Darmstadt, Germany
xMAP is a registered trademark of Luminex Corp
Application
MILLIPLEX® Qualified assays undergo rigorous assay development, verification, and Quality Control testing to achieve optimal performance. Simultaneously analyze up to 5 analytes in human serum, plasma, and cell culture supernatants.Analytes included: Lactotransferrin, Lipocalin-2/NGAL, Neutrophil Elastase-2 (ELA2), Resistin, Thrombospondin-1 (TSP-1)Assay Characteristics: Refer to kit protocol for assay cross-reactivity, sensitivity, precision, and accuracy.
Disclaimer
For research use only. Not for use in diagnostic procedures.Label License/Sticker for Assay Product:By opening the packaging containing this Assay Product (which contains fluorescently labeled microsphere beads authorized by Luminex Corporation) or using this Assay Product in any manner, you are consenting and agreeing to be bound by the End User Terms and Conditions and the End User License Agreement available at http://support.diasorin.com/end-user-terms-and-conditions/. If you do not agree to all of the terms and conditions, you must promptly return this Assay Product for a full refund prior to using it in any manner.
Features and Benefits
Comprehensive Sepsis Biomarker Coverage: Luminex® xMAP® platform simultaneously quantitates 5 critical sepsis biomarkers (Lactotransferrin, Neutrophil Elastase-2, NGAL/Lipocalin-2, Resistin, Thrombospondin-1) targeting key pathways in sepsis pathogenesis and organ dysfunction.Complete Assay Solution: Ready-to-use 96-well format includes lyophilized standard cocktail and two internal quality controls, enabling analysis of up to 38 samples in duplicate with comprehensive quality assurance.Optimized Sample Processing: Compatible with human serum, plasma, and cell/tissue culture supernatants using 1:100 dilution for serum/plasma samples, maximizing sample conservation while maintaining analytical sensitivity.Sepsis Research Applications: Investigate biomarkers involved in sepsis progression from SIRS to severe sepsis and septic shock, supporting research into immune dysfunction, organ failure mechanisms, and experimental therapeutic interventions.Multi-Pathway Research Analysis: Simultaneously measure neutrophil activation, acute kidney injury markers, antimicrobial responses, metabolic dysfunction indicators, and vascular integrity markers for comprehensive sepsis research.
General description
Sepsis or SIRS (systemic inflammatory response syndrome) results from infection, whether bacterial, viral, fungal, or parasitic. The pathogenesis of sepsis is very complex. Both an innate and acquired immune response to infection interrupts homeostasis with a shift of cytokine expression that increases immunosuppression. In addition, migration of the leukocytes in the inflamed tissues secretes a tissue factor leading to the formation of thrombin, also triggering the release of chemokines and adhesion molecules through endothelial cells. Severe sepsis occurs when hypotension or hypoperfusion to one or more organs leads to organ dysfunction, which, in turn, can cause septic shock, multiple organ dysfunction syndrome (MODS) and death.
